{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:46:47Z","timestamp":1787003207459,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR2830"],"award-info":[{"award-number":["FOR2830"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.2. BA.2.86 and its JN.1 derivative evade neutralization by serum antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the immune escape of BA.2.86 and JN.1 via pseudovirus neutralization. Here we generate 33 BA.2.86 mutants, each reverting a single mutation back to BA.2. We use this library in an approach that we call reverse mutational scanning to define distinct neutralization titers against each epitope. Mutations within the receptor binding domain at K356T, V483\u0394, and to a lesser extent N460K, A484K, and F486P enhance immune escape. Interestingly, 16insMPLF within the spike N-terminal domain and P621S within S1\/S2 also significantly contribute to antibody escape of BA.2.86. Upon XBB.1.5 booster vaccination, neutralization titers against JN.1 and BA.2.86 improve considerably, and residual immune escape is driven by 16insMPLF, N460K, E554K, and to a lesser extent P621S, and A484K.<\/jats:p>","DOI":"10.1038\/s41467-025-55871-5","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:28:09Z","timestamp":1737178089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera"],"prefix":"10.1038","volume":"16","author":[{"given":"Najat","family":"Bdeir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"L\u00fcddecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-5423","authenticated-orcid":false,"given":"Henrike","family":"Maa\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-4921","authenticated-orcid":false,"given":"Ulfert","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-1330","authenticated-orcid":false,"given":"Henning","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Metzdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upasana","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3001-2478","authenticated-orcid":false,"given":"Metodi V.","family":"Stankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-7696","authenticated-orcid":false,"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-9136","authenticated-orcid":false,"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-9668","authenticated-orcid":false,"given":"Wulf","family":"Blankenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-100X","authenticated-orcid":false,"given":"Alexandra","family":"Dopfer-Jablonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-621X","authenticated-orcid":false,"given":"Georg M. N.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-778X","authenticated-orcid":false,"given":"Luka","family":"\u010ci\u010din-\u0160ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"55871_CR1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/d41586-023-02656-9","volume":"620","author":"E Callaway","year":"2023","unstructured":"Callaway, E. Why a highly mutated coronavirus variant has scientists on alert. Nature 620, 934 (2023).","journal-title":"Nature"},{"key":"55871_CR2","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/vaccines11111634","volume":"11","author":"D Focosi","year":"2023","unstructured":"Focosi, D., Spezia, P. G. & Maggi, F. SARS-CoV-2 BA.2.86 (\u201cPirola\u201d): Is it Pi or Just Another Omicron Sublineage? Vaccines 11, 1634 (2023).","journal-title":"Vaccines"},{"key":"55871_CR3","first-page":"1029","volume":"330","author":"E Harris","year":"2023","unstructured":"Harris, E. CDC Assesses Risk From BA.2.86, Highly Mutated COVID-19 Variant. JAMA 330, 1029 (2023).","journal-title":"JAMA"},{"key":"55871_CR4","doi-asserted-by":"publisher","first-page":"2300460","DOI":"10.2807\/1560-7917.ES.2023.28.36.2300460","volume":"28","author":"M Rasmussen","year":"2023","unstructured":"Rasmussen, M. et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Eur. Surveill. 28, 2300460 (2023).","journal-title":"Eur. Surveill."},{"key":"55871_CR5","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S1473-3099(23)00620-5","volume":"23","author":"DL Wannigama","year":"2023","unstructured":"Wannigama, D. L. et al. Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. Lancet Infect. Dis. 23, e464\u2013e466 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"55871_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.15585\/mmwr.mm7243a2","volume":"72","author":"AS Lambrou","year":"2023","unstructured":"Lambrou, A. S. et al. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.2.86 - Worldwide, July-October 2023. MMWR Morb. Mortal. Wkly Rep. 72, 1162\u20131167 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"55871_CR7","doi-asserted-by":"publisher","first-page":"2300489","DOI":"10.2807\/1560-7917.ES.2023.28.39.2300489","volume":"28","author":"L Reeve","year":"2023","unstructured":"Reeve, L. et al. High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023. Eur. Surveill. 28, 2300489 (2023).","journal-title":"Eur. Surveill."},{"key":"55871_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"55871_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01110-21","volume":"96","author":"S Lusvarghi","year":"2022","unstructured":"Lusvarghi, S. et al. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J. Virol. 96, e0111021 (2022).","journal-title":"J. Virol."},{"key":"55871_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"55871_CR11","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/S1473-3099(23)00573-X","volume":"23","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 23, e457\u2013e459 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"55871_CR12","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S1473-3099(23)00575-3","volume":"23","author":"K Uriu","year":"2023","unstructured":"Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 23, e460\u2013e461 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"55871_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-023-06750-w","volume":"624","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 624, 639\u2013644 (2023).","journal-title":"Nature"},{"key":"55871_CR14","doi-asserted-by":"publisher","unstructured":"Qian, W. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv, https:\/\/doi.org\/10.1101\/2023.11.26.568730 (2023).","DOI":"10.1101\/2023.11.26.568730"},{"key":"55871_CR15","doi-asserted-by":"publisher","unstructured":"Dadonaite, B. et al. Full-spike deep mutational scanning helps predict the evolutionary success of SARS-CoV-2 clades. bioRxiv, https:\/\/doi.org\/10.1101\/2023.11.13.566961 (2023).","DOI":"10.1101\/2023.11.13.566961"},{"key":"55871_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.chom.2022.07.006","volume":"30","author":"C Pastorio","year":"2022","unstructured":"Pastorio, C. et al. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. Cell Host Microbe 30, 1255\u20131268.e1255 (2022).","journal-title":"Cell Host Microbe"},{"key":"55871_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/v15112153","volume":"15","author":"L Abassi","year":"2023","unstructured":"Abassi, L. et al. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses 15, 2153 (2023).","journal-title":"Viruses"},{"key":"55871_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1056\/NEJMc2214314","volume":"388","author":"J Miller","year":"2023","unstructured":"Miller, J. et al. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N. Engl. J. Med. 388, 662\u2013664 (2023).","journal-title":"N. Engl. J. Med."},{"key":"55871_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","volume":"23","author":"C Yue","year":"2023","unstructured":"Yue, C. et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect. Dis. 23, 278\u2013280 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"55871_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"55871_CR21","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347.e2316 (2021).","journal-title":"Cell"},{"key":"55871_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.cmi.2022.05.002","volume":"28","author":"C Vellas","year":"2022","unstructured":"Vellas, C. et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin. Microbiol. Infect. 28, 1297\u20131299 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"55871_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101349","volume":"62","author":"AZ Mykytyn","year":"2023","unstructured":"Mykytyn, A. Z., Fouchier, R. A. & Haagmans, B. L. Antigenic evolution of SARS coronavirus 2. Curr. Opin. Virol. 62, 101349 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"55871_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111903","volume":"42","author":"J Huo","year":"2023","unstructured":"Huo, J. et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Rep. 42, 111903 (2023).","journal-title":"Cell Rep."},{"key":"55871_CR25","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.chom.2022.09.015","volume":"30","author":"P Qu","year":"2022","unstructured":"Qu, P. et al. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30, 1518\u20131526.e1514 (2022).","journal-title":"Cell Host Microbe"},{"key":"55871_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","volume":"596","author":"K Tunyasuvunakool","year":"2021","unstructured":"Tunyasuvunakool, K. et al. Highly accurate protein structure prediction for the human proteome. Nature 596, 590\u2013596 (2021).","journal-title":"Nature"},{"key":"55871_CR27","doi-asserted-by":"publisher","unstructured":"Richard, E. et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv, https:\/\/doi.org\/10.1101\/2021.10.04.463034 (2022).","DOI":"10.1101\/2021.10.04.463034"},{"key":"55871_CR28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2023.12.025","volume":"187","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell 187, 596\u2013608.e517 (2024).","journal-title":"Cell"},{"key":"55871_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15092","volume":"8","author":"Y Yuan","year":"2017","unstructured":"Yuan, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017).","journal-title":"Nat. Commun."},{"key":"55871_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29124","volume":"95","author":"P Colson","year":"2023","unstructured":"Colson, P. et al. Emergence of a second SARS-CoV-2 variant with a tremendous genetic leap from its ancestors. J. Med. Virol. 95, e29124 (2023).","journal-title":"J. Med. Virol."},{"key":"55871_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1288794","volume":"14","author":"M Katzmarzyk","year":"2023","unstructured":"Katzmarzyk, M. et al. Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera. Front. Immunol. 14, 1288794 (2023).","journal-title":"Front. Immunol."},{"key":"55871_CR32","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S1473-3099(23)00588-1","volume":"23","author":"DJ Sheward","year":"2023","unstructured":"Sheward, D. J. et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect. Dis. 23, e462\u2013e463 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"55871_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00090-22","volume":"96","author":"B Berkhout","year":"2022","unstructured":"Berkhout, B. & Herrera-Carrillo, E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. J. Virol. 96, e0009022 (2022).","journal-title":"J. Virol."},{"key":"55871_CR34","doi-asserted-by":"publisher","unstructured":"Raglow, Z. et al. SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis. medRxiv, https:\/\/doi.org\/10.1101\/2023.08.22.23294416 (2023).","DOI":"10.1101\/2023.08.22.23294416"},{"key":"55871_CR35","doi-asserted-by":"publisher","unstructured":"Stankov, M. V. et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect. Dis., https:\/\/doi.org\/10.1016\/s1473-3099(23)00690-4 (2023).","DOI":"10.1016\/s1473-3099(23)00690-4"},{"key":"55871_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"55871_CR37","doi-asserted-by":"publisher","first-page":"e159062","DOI":"10.1172\/JCI159062","volume":"132","author":"N Suryadevara","year":"2022","unstructured":"Suryadevara, N. et al. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. J. Clin. Invest 132, e159062 (2022).","journal-title":"J. Clin. Invest"},{"key":"55871_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108254","volume":"26","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 26, 108254 (2023).","journal-title":"iScience"},{"key":"55871_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e278 (2023).","journal-title":"Cell"},{"key":"55871_CR40","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.chom.2022.09.002","volume":"30","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe 30, 1512\u20131517.e1514 (2022).","journal-title":"Cell Host Microbe"},{"key":"55871_CR41","doi-asserted-by":"publisher","DOI":"10.1099\/acmi.0.000057","volume":"1","author":"S Lester","year":"2019","unstructured":"Lester, S. et al. Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies. Access Microbiol. 1, e000057 (2019).","journal-title":"Access Microbiol."},{"key":"55871_CR42","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/diagnostics11060994","volume":"11","author":"AMK Tolah","year":"2021","unstructured":"Tolah, A. M. K. et al. Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. Diagnostics 11, 994 (2021).","journal-title":"Diagnostics"},{"key":"55871_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq2427","volume":"7","author":"J Quandt","year":"2022","unstructured":"Quandt, J. et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci. Immunol. 7, eabq2427 (2022).","journal-title":"Sci. Immunol."},{"key":"55871_CR44","doi-asserted-by":"publisher","first-page":"e25858","DOI":"10.1371\/journal.pone.0025858","volume":"6","author":"M Berger Rentsch","year":"2011","unstructured":"Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One 6, e25858 (2011).","journal-title":"PLoS One"},{"key":"55871_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55871-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55871-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55871-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:28:11Z","timestamp":1737178091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55871-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55871"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-55871-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.C.-S. served as an advisor to Sanofi unrelated to this work. G.M.N.B. served as advisor for Moderna unrelated to this work, A.D.-J. served as an advisor for Pfizer unrelated to this work, S.P. and M.H. conducted contract research (testing of vaccinee plasma for neutralizing activity against SARS-CoV-2) for Valneva unrelated to this work. S.P. served as advisor for BioNTech, unrelated to this work. H.J. served as advisor on COVID neutralization assays for WHO and CEPI, unrelated to this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"809"}}